 |
|
MET tyrosine kinase inhibitor PF-04217903
An orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903 selectively binds to and inhibits mesenchymal epithelial transition (MET or c-Met), disrupting the c-Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction of death in tumor cells expressing c-Met. The receptor tyrosine kinase c-Met, also known as hepatocyte growth factor (HGF) receptor, is overexpressed or mutated in many tumor cell types, playing an important role in tumor cell proliferation, survival, invasion, and metastasis and angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code name: | | PF-04217903 | | |
| Previous: | Mesnex, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine, MET receptor tyrosine kinase inhibitor SGX523, Met tyrosine kinase inhibitor BMS-777607, MET tyrosine kinase inhibitor PF-02341066 | | Next: | Metastat, Metastron, metformin hydrochloride, methadone hydrochloride, Methadose |
|
|
